


European Journal of Immunology

Supporting Information for

DOI 10.1002/eji.201747024


Cristina Cirauqui, Cristina Benito-Villalvilla, Silvia Sánchez-Ramón, Sofía Sirvent, Carmen M. Diez-Rivero, Laura Conejero, Paola Brandi, Lourdes Hernández-Cillero, Juliana Lucía Ochoa, Beatriz Pérez-Villamil, David Sancho, José Luis Subiza and Oscar Palomares

Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways



Cirauqui *et al.* Supplementary Figure 1

Supplementary Figure 1. Messenger RNA expression levels of IL-12p40, IL-12p35, TNF- α , IL-6, IL-1 β , IL-23, and IL-10 genes in hmoDCs treated with MV130 for 0, 1, 3, 6 and 24 hours. Arbitrary units relative to EF1 α are $2^{-\Delta CT}$ values multiplied by 10^4 , with ΔCT defined as the difference between the cycle threshold value for the gene of interest and EF1 α . Data are the mean $\pm$ s.e.m (n=4).



Cirauqui *et al.* Supplementary figure 2

Supplementary Figure 2. The graphs display the percentage of inhibition of TNF- α , IL-6, IL-1 β , IL-23 and IL-10 production by MV130 or MV140-treated hmoDCs by the inhibitor Pepinh-MYD related to vehicle controls (Pepinh-Control). Results are the mean $\pm$ s.e.m. (n=6-8). Unpaired t test * P < 0.05, ** P < 0.01.